Bone Affecting Patents (Class 514/16.7)
  • Patent number: 11492382
    Abstract: Provided in this disclosure are chimeric peptides that include a spacer domain, the spacer domain itself, substrates (e.g., implants) coated with the chimeric peptides, and methods for making and using the coated substrates.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: November 8, 2022
    Assignee: UNIVERSITY OF KANSAS
    Inventors: Candan Tamerler-Behar, Emily Caitlyn Wisdom, Kyle Boone
  • Patent number: 11253628
    Abstract: This disclosure relates to methods for promoting bone formation or reducing bone destruction. This disclosure also relates to methods for promoting the recruitment of mesenchymal stem cells (MSCs) to a local site of injury or surgical intervention in bone to promote healing. In addition, this disclosure relates to methods for reducing or preventing mineral formation or bone growth, or reducing bone mass. The methods disclosed herein are useful for treating conditions such as osteopetrosis or osteoradionecrosis.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: February 22, 2022
    Assignee: The Research Foundation for the State University of New York
    Inventors: Bryan S. Margulies, Sean D. Deboyace
  • Patent number: 11241502
    Abstract: The present invention provides stable pharmaceutical compositions of pegylated carfilzomib compounds, methods for preparing the compositions, and uses of the compositions for treating cancer, including hematologic malignancies such as multiple myeloma. The compositions can be stored in frozen form or lyophilized to dry solid form.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: February 8, 2022
    Assignee: AMGEN INC.
    Inventors: Alona Teran, William Callahan, Qahera Munaim, Rahul Kaushik
  • Patent number: 11224661
    Abstract: The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: January 18, 2022
    Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/S
    Inventors: Kennett Sprogøe, Harald Rau, Ana Bernhard, Ulrich Hersel, Felix Cleenmann, Thomas Wegge
  • Patent number: 10960108
    Abstract: A method of making a bone matrix includes exposing a bone tissue to a solution including a surfactant and a protease; treating the bone tissue with an acid solution following exposing the bone tissue; and electrophoretically treating the acid treated bone tissue. A bone matrix has a DNA content of not greater than 0.1 micrograms per milligram sample and a modulus in a range of 180 kPa to 250 kPa.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: March 30, 2021
    Assignee: FABRICO TECHNOLOGY INC
    Inventors: Joseph Oleniczak, Robert Chin
  • Patent number: 10918629
    Abstract: The disclosure relates to the field of lymphedema therapy, more specifically, to a new pharmacological strategy to rescue the failed lymph pump system that can supplement, enhance or replace current therapies.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: February 16, 2021
    Assignee: The Curators of the University of Missouri
    Inventor: Michael John Davis
  • Patent number: 10864194
    Abstract: The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: December 15, 2020
    Assignee: Clementia Pharmaceuticals Inc.
    Inventors: Clarissa Desjardins, Donna Roy Grogan, Jeffrey Neal Packman, Mark Harnett
  • Patent number: 10688178
    Abstract: Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: June 23, 2020
    Assignees: Osaka University, Chugai Seiyaku Kabushiki Kaisha
    Inventors: Atsushi Kumanogoh, Ryusuke Omiya, Hiroyuki Tsunoda, Takeshi Baba, Sachiyo Suzuki, Yuri Teranishi
  • Patent number: 10610506
    Abstract: The present invention relates to use of ornithine in the manufacture of a medicament for use in combination with at least one of phenylacetate and phenylbutyrate for preventing or treating liver decompensation or hepatic encephalopathy. The invention also relates to use of at least one of phenylacetate and phenylbutyrate in the manufacture of a medicament for use in combination with ornithine for preventing or treating liver decompensation or hepatic encephalopathy.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: April 7, 2020
    Assignee: UCL BUSINESS LTD
    Inventors: Rajiv Jalan, Kamal Nayan Jalan
  • Patent number: 10550165
    Abstract: (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFR?-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. (Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFR?-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFR?-positive cells.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: February 4, 2020
    Assignees: STEMRIM INC., OSAKA UNIVERSITY
    Inventors: Katsuto Tamai, Takehiko Yamazaki, Tsutomu Kanezaki, Shigeru Sakurai, Yukiko Noguchi, Mayumi Endo, Natsumi Hamabuchi, Kana Naito
  • Patent number: 10548923
    Abstract: A method of enhancing the binding of growth factors and cell cultures to a demineralized allograft bone material which includes applying ex vivo an effective quantity of an ionic force change agent to at least a portion of the surface of a demineralized allograft bone material to produce a binding-sensitized demineralized allograft bone material and implanting the binding-sensitized demineralized allograft bone material into a host bone. The ionic force change agent may include at least one of enzymes, pressure, chemicals, heat, sheer force, oxygen plasma, supercritical nitrogen, supercritical carbon, supercritical water or a combination thereof. A molecule, a cell culture, or a combination thereof is administered to the binding-sensitized demineralized allograft bone material.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: February 4, 2020
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Guobao Wei, Susan J. Drapeau
  • Patent number: 10485853
    Abstract: The invention relates to a cheese includes angiogenin and/or angiogenin hydrolysate in an amount of 6.5 mg/100 g to 160 mg/100 g, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.3 to 33.
    Type: Grant
    Filed: July 31, 2012
    Date of Patent: November 26, 2019
    Assignee: MEGMILK SNOW BRAND CO., LTD.
    Inventors: Aiko Ohmachi, Hiroaki Matsuyama, Yoshikazu Morita, Yuko Ishida, Takayuki Nara, Ken Kato, Atsushi Serizawa, Hiroshi Ueno, Hiroshi Urazono
  • Patent number: 10406264
    Abstract: The present invention relates to a peptide having the ability to bind specifically to the surface of titanium. The titanium-binding peptide according to the present invention is fixed securely to the titanium surface so that the activity of a physiologically active substance linked to the peptide can be stably maintained over a long period of time. Thus, the peptide can be effectively used for surgical regeneration therapy.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: September 10, 2019
    Assignees: NANO INTELLIGENT BIOMEDICAL ENGINEERING CORPORATION CO., LTD., Seoul National University R&DB Foundation
    Inventors: Chong-Pyoung Chung, Yoon Jeong Park, Jue-Yeon Lee, Yeonsu Kim, Dong Woo Lee
  • Patent number: 10385104
    Abstract: The present invention relates to peptides comprising analogues of VDAC1-derived peptides having improved pharmacokinetic characteristics compared to the native parent peptides, which are effective in impairing cell energy production, in inducing apoptosis and cell death, particularly of cancerous cells, in eliminating cancer stem cells and in reducing symptoms associated with fat accumulation in liver cells particularly with nonalcoholic fatty liver disease (NAFLD) and symptoms associated thereto.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: August 20, 2019
    Assignees: B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY, THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD.
    Inventor: Varda Shoshan-Barmatz
  • Patent number: 10350188
    Abstract: Use of Neu1 sialidase inhibitors for the treatment of cancer as a monotherapy or in combination with known chemotherapeutics. Preferably, Neu1 sialidase inhibitors are oseltamivir phosphate or 2-deoxy-2,3-dehydro-N-acetylneuraminic acid (DANA) or analogs thereof.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: July 16, 2019
    Inventors: Paul Zachary Josefowitz, Constantin Melas-Kyriazl, Myron R. Szewczuk
  • Patent number: 10213527
    Abstract: An isolated peptide is disclosed. The peptide comprises a titanium oxide binding amino acid sequence connected to a heterologous biologically active amino acid sequence via a beta sheet breaker linker, wherein: (i) the titanium oxide binding amino acid sequence is selected to bind coordinatively with titanium oxide; (ii) the titanium oxide binding amino acid sequence is selected to induce a beta sheet structure; and (ii) the titanium oxide binding amino acid sequence binds to titanium oxide with a higher affinity than said biologically active amino acid sequence binds to the titanium oxide under physiological conditions. Use of the peptides and titanium devices comprising same are also disclosed.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: February 26, 2019
    Assignee: Ben-Gurion University of the Negev Research and Development Authority
    Inventors: Hanna Rapaport, Anna Gittelman
  • Patent number: 10017766
    Abstract: The invention relates to si RNA molecules and their use in methods and pharmaceutical compositions for inhibiting the expression of the FLAP gene. The invention also relates to the use of said si RNAs molecules in the treatment and/or prevention of an eye condition characterized by increased expression and/or activity of FLAP gene, preferably said eye condition is conjunctivitis and/or an ocular allergy such as seasonal allergic conjunctivitis, perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, and giant papillary conjunctivitis.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: July 10, 2018
    Assignee: SYLENTIS SAU
    Inventors: Ana Isabel Jimenez, Covadonga Pañeda, Tamara Martinez
  • Patent number: 9951103
    Abstract: There is described a material comprising tapes, ribbons, fibrils or fibers characterized in that each of the ribbons, fibrils or fibers have an antiparallel arrangement of peptides in a ?-sheet tape-like substructure.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: April 24, 2018
    Assignee: University of Leeds
    Inventors: Neville Boden, Amalia Aggeli, Eileen Ingham, Jennifer Kirkham
  • Patent number: 9884072
    Abstract: Disclosed herein are antisense compounds and methods for decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) or Lp(a). Certain diseases, disorders or conditions related to apo(a) or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The antisense compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: February 6, 2018
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Susan M. Freier, Marc Lim, Andrew Dibble
  • Patent number: 9566257
    Abstract: The present invention relates to use of ornithine in the manufacture of a medicament for use in combination with at least one of phenylacetate and phenylbutyrate for preventing or treating liver decompensation or hepatic encephalopathy. The invention also relates to use of at least one of phenylacetate and phenylbutyrate in the manufacture of a medicament for use in combination with ornithine for preventing or treating liver decompensation or hepatic encephalopathy.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: February 14, 2017
    Assignee: UCL Business PLC
    Inventors: Rajiv Jalan, Kamal Nayan Jalan
  • Patent number: 9555053
    Abstract: The present invention relates to a compound selected among the synthetic polysulphated oligosaccharides having 1 to 4 ose units and the salts and complexes thereof to be used for the treatment of wounds resulting in pathological scars selected among hypertrophic, retractile or atrophic scars. Said use is preferred in particular in patients that have a predisposition to developing hypertrophic, retractile or atrophic scars. According to a second aspect, the invention also relates to said compound for the use thereof in order to inhibit the differentiation of fibroblasts into myofibroblasts during the cicatrisation of wounds resulting in pathological scars selected among hypertrophic, retractile or atrophic scars.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: January 31, 2017
    Assignees: LABORATOIRES URGO, SOCIETE DE DEVELOPPEMENT ET DE RECHERCHE INDUSTRIELLE
    Inventors: Marielle Bouschbacher, Christelle Laurensou
  • Patent number: 9512404
    Abstract: The present invention relates to nanofibers. In particular, the present invention provides aligned nanofiber bundle assemblies. In some embodiments, the aligned nanofiber bundle assemblies are used for tissue regeneration, controlled growth of cells, and related methods (e.g., diagnostic methods, research methods, drug screening).
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: December 6, 2016
    Assignee: Northwestern University
    Inventors: Samuel I. Stupp, Shuming Zhang, Alvaro Mata, Megan A. Greenfield
  • Patent number: 9393270
    Abstract: A vacuum container supports a macroscopic sized cancellous device fully immersed within a solution of a bone growth promoting substance in a sealed chamber. The solution may include one of a Demineralized Bone Matrix (DBM) solution, a morphegenic protein solution, or a stem cell solution. A vacuum creating device is in fluid communication with the sealed chamber, and is operable to remove air from within the sealed chamber to create a vacuum therein. Removing air from the sealed chamber also removes air from a plurality of voids in the cancellous device, which allows the solution to fill the voids and saturate the cancellous device in preparation for use as a bone graft. The cancellous device may further be agitated while the air is being removed from the voids in the cancellous device to further promote saturation of the voids in the cancellous device with the solution.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: July 19, 2016
    Inventor: Vittorio M. Morreale
  • Patent number: 9393287
    Abstract: Compositions and methods are provided for promoting organ development in warm blooded animals, and in particular in certain aspects a premature infant or fetus. Compositions and methods are also provided for the administration of at least one colony stimulating factor-1 protein (CSF-1), precursor, variant, analog, derivative thereof, or combinations thereof, or otherwise, at least one nucleic acid molecule encoding colony stimulating factor-1 protein (CSF-1), precursor, variant, analog, derivative thereof, or combinations thereof.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: July 19, 2016
    Assignee: KINTAN PTY LTD.
    Inventors: Sharon Denise Ricardo, David Arthur Hume, Melissa Helen Little, Christina Victoria Jones
  • Patent number: 9333237
    Abstract: A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2. BBP increases the overall osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: May 10, 2016
    Assignees: The United States of America National Institutes of Health (NIH), U.S. Dept of Health and Human Services (DHHS), The Regents of the University of California
    Inventors: Samuel S. Murray, Elsa J. Murray, Keyvan Behnam
  • Patent number: 9155746
    Abstract: Disclosed herein are methods of promoting osteogenesis in a subject, comprising administering a composition comprising a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA). Also disclosed herein are methods of promoting osteogenesis in a subject in need of such promotion, comprising administering a composition comprising a therapeutically effective amount of at least one CSA. Additionally, disclosed herein are compounds and compositions comprising at least one CSA, or a pharmaceutically acceptable salt thereof, for use in the treatment of bone disease or the treatment of broken bones. Kits comprising such compositions and instructions on such methods are also contemplated herein.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: October 13, 2015
    Assignee: Brigham Young University
    Inventors: Carl Genberg, Paul B. Savage
  • Patent number: 9095551
    Abstract: An object of the present invention is to enable the repair and regeneration of articular cartilage, which could not be achieved by conventional therapies, and to provide a safe and inexpensive agent that is effective for the treatment of joint diseases such as osteoarthritis. According to the present invention, a combined formulation for simultaneously, separately, or sequentially administering a hyaluronic acid and an animal mucin-type glycoprotein for the treatment of joint diseases is provided.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: August 4, 2015
    Assignees: RIKEN, TOKAI UNIVERSITY EDUCATIONAL SYSTEM
    Inventors: Kiminori Ushida, Koji Kihira, Takayuki Baba, Kayoko Taniguchi, Makoto Urai, Masato Sato, Naoshi Ohta, Joji Mochida
  • Patent number: 9068016
    Abstract: The present invention provides conjugates of cytokines and targeting peptides that is able to bind to a receptor expressed on tumor-associated vessels or to a component of the extracellular matrix associated to the tumor vessels, for treatment of malignant pleural mesothelioma. In particular, the invention provides conjugates comprising the cytokine TNF linked to a peptide containing the NGR motif. The invention further provides pharmaceutical compositions comprising such conjugate and pharmaceutical formulations comprising conjugates dissolved in appropriate buffers.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: June 30, 2015
    Assignee: Molmed S.P.A
    Inventors: Claudio Bordignon, Antonio Lambiase
  • Patent number: 9050300
    Abstract: The present invention relates to the clinical application of BBP, alone or in combination with other growth factors, for use in bone healing applications, such as spinal surgery. Additional applications include use in orthopedic implantable prostheses and implantation into other surgical sites (e.g., surgical reconstruction, regional osteopenia, etc.) where bone is desired.
    Type: Grant
    Filed: April 5, 2013
    Date of Patent: June 9, 2015
    Assignees: The Regents of The University of California, The United States of America Represented by The Department of Veterans Affairs
    Inventors: Samuel S. Murray, Elsa J. Brochmann-Murray, Keyvan Behnam, Jeffrey C. Wang
  • Publication number: 20150141333
    Abstract: A malleable bone graft composition is described. The composition comprises: (a) keratose; (b) particulate filler; (c) antibiotic; and (d) water. The invention may be provided in sterile form in an container, and optionally lyophilized. Methods of treating a fracture with such compositions are also described.
    Type: Application
    Filed: November 19, 2014
    Publication date: May 21, 2015
    Inventor: Mark E. Van Dyke
  • Publication number: 20150139907
    Abstract: This invention provides novel methods for inducing hair growth and/or inhibiting hair loss and/or inducing nail growth in a mammal. In various embodiments the methods involve administering, e.g., to a mammal in need thereof, a calcium-binding peptide and/or peptide-like moiety in an amount sufficient to induce hair growth and/or to inhibit hair loss. In certain embodiments the agent is topically and/or transdermally administered.
    Type: Application
    Filed: October 14, 2014
    Publication date: May 21, 2015
    Inventors: Daniel K. Yarbrough, Xiaoyang Wu, Wenyuan Shi, Maxwell H. Anderson
  • Publication number: 20150133367
    Abstract: The present invention includes a novel class of highly specific protease inhibitors. In one embodiment, the inhibitors of the invention are ?-helical in structure. In another embodiment, the present invention represents the first demonstration of a highly specific cysteine protease inhibitor.
    Type: Application
    Filed: April 26, 2013
    Publication date: May 14, 2015
    Inventor: Doron C. Greenbaum
  • Publication number: 20150126452
    Abstract: The present invention relates to a method for assembling (monomeric or oligomeric) proteins and peptide structures to multimeric protein or peptide structures. The present invention also provides a method for preparing peptide based polymers by crosslinking such multimeric proteins or peptides obtainable according to the inventive method and their use as polymers, for amphiphilic applications, as protein based detergents, for forming artificial organelles, etc. Disclosed are furthermore novel protein or peptide structures, nucleic acids encoding same and cloning and expression vectors suitable for carrying out the inventive method for assembling multimeric proteins or peptides.
    Type: Application
    Filed: May 28, 2013
    Publication date: May 7, 2015
    Inventors: Stefan Schiller, Matthias Huber
  • Publication number: 20150125537
    Abstract: There is provided a bone filler material comprising a plurality of particles, each particle comprising a biodegradable outer shell and an inner core. There is also provided an implant prepared from the same, methods of using the same and preparing the same.
    Type: Application
    Filed: November 7, 2014
    Publication date: May 7, 2015
    Inventors: Cho Hong James Goh, Pujiang Shi, Hee Kit Wong, Yong Zhang, Sunny Akogwu Abbah, Jun Li
  • Publication number: 20150119334
    Abstract: An isolated peptide is disclosed. The peptide comprises a titanium oxide binding amino acid sequence connected to a heterologous biologically active amino acid sequence via a beta sheet breaker linker, wherein: (i) the titanium oxide binding amino acid sequence is selected to bind coordinatively with titanium oxide; (ii) the titanium oxide binding amino acid sequence is selected to induce a beta sheet structure; and (ii) the titanium oxide binding amino acid sequence binds to titanium oxide with a higher affinity than said biologically active amino acid sequence binds to the titanium oxide under physiological conditions. Use of the peptides and titanium devices comprising same are also disclosed.
    Type: Application
    Filed: June 3, 2013
    Publication date: April 30, 2015
    Applicant: Ben-Gurion niversity of the Negev Research and Development Authority
    Inventors: Hanna Rapaport, Anna Gittelman
  • Patent number: 8999935
    Abstract: The present invention is directed to a method of treating, preventing, or reducing the risk of bone deterioration or osteoporosis in a peri- or post-menopausal female subject. The method involves selecting a peri- or post-menopausal female subject in need of treating, preventing, or reducing the risk of bone deterioration or osteoporosis and administering hepcidin to the selected subject under conditions effective to treat, prevent, or reduce the risk of bone deterioration or osteoporosis.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: April 7, 2015
    Assignee: New York University
    Inventor: Xi Huang
  • Patent number: 8987201
    Abstract: Black bear parathyroid hormone (PTH) and functional fragments thereof are provided. Also provided are methods of using black bear PTH and functional fragments for increasing cAMP in a bone-forming cell; reducing apoptosis in a bone-forming cell; decreasing the ratio of expression levels of Bax protein to Bcl-2 protein in a bone-forming cell; increasing the expression level of one or more of a bone matrix protein, a transcriptional activator, or a transcriptional regulator in a bone-forming cell; enhancing bone mineral density, increasing bone mass, decreasing bone loss, or reducing the incidence of bone fractures, or any combination thereof, in a subject; also provided are antibodies directed against black bear parathyroid hormone (PTH) and functional fragments thereof.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: March 24, 2015
    Assignee: Michigan Technological University
    Inventor: Seth W. Donahue
  • Patent number: 8987203
    Abstract: The present invention relates to methods for selecting a candidate therapeutic agent for controlling mineralization of an extracellular matrix in a tissue of a subject. The invention further relates to a cell culture mineralization model comprising a culture of an extracellular matrix producing cell under conditions that support extracellular matrix formation and matrix maturation, a test compound, and means and methods for determining in expression levels of genes encoding matrix proteins.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: March 24, 2015
    Assignee: Arcarios B.V.
    Inventors: Johannes Petrus Thomas Maria Van Leeuwen, Hermanus Johannes Marco Eijken
  • Patent number: 8987204
    Abstract: It is an object of the present invention to provide a bone regeneration agent and a bone supplementation formulation, in which a supplementation material itself is capable of promoting bone regeneration. The present invention provides a bone regeneration agent which comprises a gelatin having an amino acid sequence derived from a partial amino acid sequence of collagen.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: March 24, 2015
    Assignee: FUJIFILM Coporation
    Inventors: Takahiro Hiratsuka, Shouji Ooya, Ichiro Nishimura
  • Publication number: 20150080312
    Abstract: This invention relates to an isolated, compound of Formula (1) or derivatives or pharmaceutically acceptable salts thereof. The invention also includes all isomeric and tautomeric forms of the compound of Formula (1) or the derivatives thereof. The present invention further relates to processes for the production of the compound of Formula (1) by fermentation of the fungal strain of Actinomycetes (PM0895172/MTCC 684), pharmaceutical compositions comprising the compound of Formula (1) as the active ingredient; and use of the compounds or composition containing them in the treatment of cancer.
    Type: Application
    Filed: May 6, 2013
    Publication date: March 19, 2015
    Applicant: PIRAMAL ENTERPRISES LIMITED
    Inventors: Prabhu Dutt Mishra, Sreekumar Sankaranarayanan Eyyammadichiyl, Saji David George, Shailendra Sonawane, Narayan Subhash Chakor, Abhijit Roychowdhury, Rajiv Sharma
  • Publication number: 20150073476
    Abstract: The present invention relates to compositions comprising shape memory polymer (SMP) materials and uses thereof. Particularly, although not exclusively, the present invention relates to biocompatible shape memory polymer (SMP) materials and uses thereof in the medical field.
    Type: Application
    Filed: October 5, 2012
    Publication date: March 12, 2015
    Inventors: Malcolm Brown, Horacio Montes de Oca Balderas, Michael Andrew Hall, Alan William Bull, David Franklin Farrar, Philip Caton-Rose, Philip David Coates, Glen Thompson, Michael Martyn, Ian MacMillan Ward, Mark James Bonner, Peter John Hine, Paul Unwin, Robin Anthony Chivers, Michael Woodhead
  • Patent number: 8975231
    Abstract: A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2, as do endogenous forms of BBP, and sequence conservation between species results in a variety of useful BBP compositions. BBP increases the over-all osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: March 10, 2015
    Assignees: The Regents of the University of California, The United States of America represented by the Department of Veterans Affairs
    Inventors: Samuel S. Murray, Elsa J. Brochmann-Murray, Jeffrey Wang, Keyvan Behnam
  • Patent number: 8969296
    Abstract: The present invention relates to a GFP-CAP peptide having an amino acid sequence derived from TGF-?1 (transforming growth factor-?1) and a cell adhesion sequence, wherein the amino acid sequence derived from TGF-?1 consists of the amino acid sequence of SEQ ID NO:1 and the TGFP-CAP peptide is represented by the following formula I: Ile-Trp-Ser-Leu-Asp-Thr-Gln-Tyr-Cell adhesion sequence (I). The TGFP-CAP peptide of the present invention exhibits excellent anti-angiogenic activity. In addition, the TGFP-CAP peptide of the present invention prevents effectively melanin generation in skin to have skin whitening effects. The present peptide shows much higher stability and permeability to skin than natural-occurring TGF-?1. Such plausible activities and safety of the present peptide enable advantageously to application to drugs, quasi-drugs and cosmetics.
    Type: Grant
    Filed: September 12, 2007
    Date of Patent: March 3, 2015
    Assignee: Caregen Co., Ltd
    Inventors: Yong-Ji Chung, Young Deug Kim, Eun Mi Kim, Jun Young Choi, Jin Seuk Kim, Sang Su Song, Kyoung Mi Cho
  • Publication number: 20150056163
    Abstract: The present invention relates to methods for preventing or treating Human Immunodeficiency Virus (HIV) infection, inflammatory conditions, and graft-versus-host-disease (GVHD) in a subject. Therapeutic compositions of the present invention comprise Leukocidin E (LukE) and/or D proteins or polypeptides. The invention further relates to methods of treating Staphylococcus aureus infection by administering a composition comprising a CCR5 antagonist or any molecule that blocks LukE/D interaction with CCR5+ cells in an amount effective to treat the S. aureus infection in the subject.
    Type: Application
    Filed: August 25, 2014
    Publication date: February 26, 2015
    Inventors: Victor J. Torres, Derya Unutmaz, Francis Alonzo, III
  • Publication number: 20150051138
    Abstract: Disclosed herein are Furin/PC inhibitors for inhibiting Furin and other Propprotein Convertases. Method of making the Furin/PC inhibitors, chemical and biological characterization of the Furin/PC inhibitors, and the use of the Furin/PC inhibitors to treat infectious diseases, cancers, and inflammatory/autoimmune disorders, are also disclosed.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 19, 2015
    Applicant: Sanford-Burnham Medical Research Institute
    Inventors: Alex Strongin, Maurizio Pellecchia, Elisa Barile
  • Publication number: 20150045304
    Abstract: The invention relates to peptides including DEDE(SSD)nDEG indicated by SEQ NO. 1, RRRDEDE(SSD)nDEG indicated by SEQ No. 2, RRRGDEDE(SSD)nDEG indicated by SEQ No. 3, and LKKLKKLDEDE(SSD)nDEG indicated by SEQ NO. 4, wherein n is an integer from 2 to 20. The invention also relates to phosphorylating these peptides at multiple amino acid sites by employing casein kinases. These phosphorylated peptides may be used in various applications such as forming mineralized collagen fibrils and biometic composites for use in tissue repair and regeneration.
    Type: Application
    Filed: November 13, 2013
    Publication date: February 12, 2015
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: ELIA BENIASH, CHARLES S. SFEIR
  • Patent number: 8952131
    Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: February 10, 2015
    Assignee: Wyeth LLC
    Inventors: Stephen Berasi, Robert Vincent Martinez, Michael John Cain, John Wozney, Howard Seeherman, Z. Sean Juo, Valerie P. Calabro, Christopher Todd Brown
  • Publication number: 20150038402
    Abstract: The present application provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.
    Type: Application
    Filed: October 21, 2014
    Publication date: February 5, 2015
    Inventors: DAVID PAUL FAIRLIE, LIGONG LIU, MEI KWAN YAU, JACKY YUNG SUEN, ROBERT REID
  • Publication number: 20150030595
    Abstract: The present invention relates to a myostatin inhibitor comprising extracellular water-soluble domains of delta-like 1 homolog (DLK1) as active ingredients. More particularly, the present invention relates to a composition for inhibiting myostatin activity, comprising, as active ingredients, extracellular water-soluble domains of DLK1 or a deletion mutant of extracellular water-soluble domains of DLK1. The myostatin inhibitor of the present invention is bonded to the myostatin or activin receptor type IIB so as to inhibit the action mechanism of the myostatin, to thereby promote myogenesis and prevent differentiation into fat cells. Therefore, the myostatin inhibitor of the present invention may be used in preventing and treating diseases such as muscular dysplasia that requires differentiation to muscular cells, or metabolic diseases.
    Type: Application
    Filed: January 3, 2013
    Publication date: January 29, 2015
    Inventors: Dong Hee Lee, Bum Chan Park, Jae Eun Park, Myeong Hee Jang, Seok Ho Yoo, Hye Nan Kim
  • Publication number: 20150030656
    Abstract: A composition comprising a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analogue is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.
    Type: Application
    Filed: August 5, 2014
    Publication date: January 29, 2015
    Inventors: Paul Zamora, Brent Lee Atkinson, Xinhua Lin, Louis A. Pena